Navigation Links
Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Date:2/23/2011

CRANBURY, N.J., Feb. 23, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it intends to offer and sell units consisting of shares of its common stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Roth Capital Partners is acting as sole book-running manager for the offering and Madison Williams and Company is acting as co-manager.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, and secondarily for its PL-3994 development programs for asthma and a development program for new peptides for sexual dysfunction.

The units are being offered by Palatin Technologies pursuant to a registration statement previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on February 23, 2011. A preliminary prospectus relating to the offering has been filed with the SEC in that registration statement and is available on the SEC's website located at www.sec.gov. Electronic copies of the preliminary prospectus relating to this offering may be obtained from Roth Capital Partners, LLC Syndicate Department, 24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and Rothecm@roth.com. Before you invest, you should read the preliminary prospectus in that registration statement and other documents Palatin Technologies has filed or will file with the SEC for more complete informat
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
2. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
4. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
5. Palatin Announces Strategic Realignment of Operations
6. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
7. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
8. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
10. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BROOK, NY (PRWEB) July 30, 2014 ... APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based ... Michael E. Hogan, Ph.D. Vice President of Life Sciences, ... mid-September. , Dr. Hogan will lead APDN’s ... form business relationships with biotech and healthcare customers, provide ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... IRVINE, Calif. , July 30, 2014 /PRNewswire/ ... on the research and development of compounds to ... in humans, today announces that its partner, CardioNova, ... Phase 1b clinical trial with AtheroNova,s lead compound, ... continuation of the AHRO-001 Phase 1 safety trial ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... ), a leading,fully integrated pharmaceutical company producing over-the-counter drugs ... appointment of Mr.,William Wei Lee as an independent member ... 4, 2009. Mr. Jiang Qi-Feng resigned from the,Board effective ...
... Aug. 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrine therapy and oncology, today announced that ... a corporate overview at the upcoming Canaccord Adams 29th ... at 2:00 p.m. (eastern time) at the Intercontinental Hotel ...
... WALTHAM, Mass., Aug. 6 Repligen Corporation (Nasdaq: RGEN ... ended June 30, 2009. Total revenue for the quarter was ... of fiscal year 2009. The prior year results were favorably ... for royalties on the U.S. sales of Orencia(R) prior to the ...
Cached Biology Technology:China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 2Repligen Reports First Quarter Fiscal Year 2010 Financial Results 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 5Repligen Reports First Quarter Fiscal Year 2010 Financial Results 6Repligen Reports First Quarter Fiscal Year 2010 Financial Results 7
(Date:7/30/2014)... distance between two points is a straight line, and ... taking the familiar axiom to heart. , Though ... intense, with each racing for the chance to fertilize ... form cooperative groups that allow them to take a ... study, conducted by Heidi Fisher, a post-doctoral student working ...
(Date:7/30/2014)... joint venture between The University of Texas at San ... Center at San Antonio, has selected the winners of ... from UTSA and Lei Huang from the Health Science ... engineered ferritins for tracking and protecting neural stem cells ... focused on finding a treatment for stroke through stem ...
(Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Development Research Centre (IDRC) together with the Canadian Institutes ... Research Council of Canada (NSERC), and the Social Sciences ... that five research teams have been awarded a total ... on Adaptation to Climate Change (IRIACC). ...
... programs -- one involving traditional health club sessions and the ... similar amounts of weight and body fat, but the online ... them live healthier and leaner lives. "It,s counter-intuitive, ... but the activities that they do in a virtual world ...
... male bird called a golden-collared manakin performs a difficult, ... scientists report that female golden-collared manakins select mates based ... "The male jumps like he,s been ... Schlinger, professor and departmental chair of integrative biology and ...
Cached Biology News:International research initiative on adaptation to climate change announces research awards 2International research initiative on adaptation to climate change announces research awards 3ACSM: Weight loss success in a 3-D virtual world 2Again, but faster! The spectacular courtship dance of a tiny bird 2Again, but faster! The spectacular courtship dance of a tiny bird 3
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: